Efficacy and safety of an expanded dulaglutide dose range: A phase 2, placebo‐controlled trial in patients with type 2 diabetes using metformin

Aims Dulaglutide, a once weekly GLP‐1 receptor agonist, is approved at two doses (1.5 and 0.75 mg) for treatment of type 2 diabetes (T2D). Two higher doses of dulaglutide (3.0 and 4.5 mg) were evaluated for safety and efficacy to determine whether these doses warrant further study for improved contr...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Diabetes, obesity & metabolism obesity & metabolism, 2019-09, Vol.21 (9), p.2048-2057
Hauptverfasser:	Frias, Juan P., Wynne, Alan G., Matyjaszek‐Matuszek, Beata, Bartaskova, Dagmar, Cox, David A., Woodward, Brad, Li, Ying G., Tham, Lai S., Milicevic, Zvonko
Format:	Artikel
Sprache:	eng
Schlagworte:	Antidiabetics Body weight Diabetes Diabetes mellitus Diabetes mellitus (non-insulin dependent) dulaglutide GLP‐1 Metformin Nausea Safety type 2 diabetes
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!